Your browser version may not work well with NCBI's Web applications. More information here...
1: J Clin Psychopharmacol. 1994 Aug;14(4):241-6.Links

A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients.

Department of Psychiatry, Innsbruck University Hospital, Austria.

The phenylpiperidine derivative paroxetine is a selective serotonin reuptake inhibitor. In a double-blind 6-week trial, paroxetine was compared with amitriptyline in hospitalized patients suffering from major depression (DSM-III). One hundred fifty-three patients were enrolled in the study in seven centers in Austria and Germany. Results showed similar efficacy of both drugs after 6 weeks. The differences between groups in Montgomery-Asberg Depression Rating Scale and Clinical Global Impression ratings did not reach statistical significance at any time. Side effects were distributed similarly but with a significantly higher incidence of anticholinergic effects in patients treated with amitriptyline (p < or = 0.001), whereas agitation and insomnia were registered more often in the paroxetine group. This study supports the antidepressive efficacy of paroxetine in a sample of severely depressed inpatients.

PMID: 7962679 [PubMed - indexed for MEDLINE]

Patient Drug Information